| Date | Title | Description |
| 03.02.2026 | Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms | Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products.
But Merck posted a modest 2026 outlook that fell short of Wall Street’s expectations, a... |
| 14.11.2025 | Stocks making the biggest premarket moves: Warner Bros. Discovery, Cidara Therapeutics, Avadel Pharmaceuticals and more | - |
| 14.11.2025 | Американская Merck приобретает производителя лекарства от гриппа Cidara Therapeutics за $9,2 млрд | В рамках сделки Merck приобретет все акции Cidara по цене $221,50 за штуку. Совет директоров обеих компаний уже утвердил условия, и завершение ожидается в первом квартале 2026 года после проведения тендерного предложения и получения всех не... |
| 13.11.2025 | Nasdaq closes higher, snapping three-day losing streak as tech stocks recover some ground | The Nasdaq Composite rebounded on Friday as investors bought up shares of key technology stocks a day after the group led Wall Street to its worst day in more than a month.
The tech-heavy Nasdaq gained 0.13% to finish at 22,900.59, snapping... |
| 08.05.2025 | Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal ... |
| 24.04.2024 | Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million | - |
| 06.03.2024 | Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024 | - |
| 12.02.2024 | Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO | - |
| 12.02.2024 | Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO | Approval triggered by positive results from ReSTORE Phase III clinical trial
Payment will advance Cidara’s Cloudbreak platform for the development of drug-Fc conjugates (DFCs)
SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics... |
| 24.04.2023 | Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™ | - |
| 04.10.2022 | Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma | /EIN News/ -- Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin
Company eligible to receive up to an additional $108M in milestones from multiple existing partnerships ... |
| 04.10.2022 | Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma | Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin
Company eligible to receive up to an additional $108M in milestones from multiple existing partnerships based on succe... |
| 21.09.2022 | San Diego antifungal player nabs priority review for bloodstream infection treatment | Cidara Therapeutics wants to make its mark in the world of antifungals, and thanks to the FDA, it may get there soon.
The San Diego-based company announced Tuesday that the FDA has given priority review to its antifungal r... |
| 18.12.2020 | Immune Regulation makes Peter Greenleaf chairman and assembles a quintet of new execs; Bob Coughlin moves on from MassBio to JLL | Peter Greenleaf
→ In September, Immune Regulation raked in $53.4 million in a Series B for two programs in rheumatoid arthritis and asthma. This week, the British biotech has named Aurinia CEO Peter Greenleaf chairman of t... |
| 29.07.2019 | Genfit's elafibranor wins orphan status for primary biliary cholangitis; Cidara stock soars on positive anti-fungal mid-stage data | → NASH hopeful Genfit has been awarded orphan drug status by US and EU regulators for its experimental drug, elafibranor, to treat patients with primary biliary cholangitis (PBC), a chronic disease in which bile ducts ... |
| 21.05.2018 | CIDARA THERAPEUTICS AND RUTGERS UNIVERSITY AWARDED $5.5 MILLION GRANT FROM NIH | - |
| 12.11.2017 | 4 newcomers to the ranks share what keeps employees motivated, happy | One worker calls the workplace “nirvana.” Another prizes the freedom to pursue an idea.” “I feel like I have a career, not a job,” said a third.
Conduct an anonymous poll of employees and you can get back gripes about bosses and low pay.
Bu... |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. It comes in response to the growing threat of drug-resistant infections — and the concerning lack of late-stage antibacterial dru... |
| 04.11.2016 | Cidara Therapeutics Receives $20M Credit Facility from Square 1 Bank | Cidara Therapeutics, Inc. (Nasdaq:CDTX), a San Diego, CA-based biotechnology company, entered into an agreement for a $20m credit facility with Square 1 Bank, a division of Pacific Western Bank.
Proceeds from the facility will provide worki... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 30.05.2016 | 5AM Ventures has raised $285M for fifth fund (Updated) | Update On Monday, it confirmed the amount in a press release on its website.
In a phone interview with 5AM Founder and Managing Partner Andrew Schwab he confirmed that 5AM Ventures V would be similar to 5 AM Ventures IV. Its investment targ... |
| 19.08.2015 | Aisling Capital launching fourth, $400M life sciences fund | A document published on the Pennsylvania Public School Employees’ Retirement System indicated the fund has a $500 million hard cap, and that PSERS will commit $50 million.
This fund is actually smaller than its third, which launched in 2009... |
| 16.03.2015 | Cidara Therapeutics Aims for $69M With Planned IPO | Cidara Therapeutics Inc. has filed to raise up to $69 million in an IPO, the San Diego biotech disclosed in a registration statement filed recently.
The biotechnology company is developing anti-infectives and immunotherapies to treat fungal... |
| 13.02.2015 | Cidara Therapeutics Completes $42M Series B |
SAN DIEGO, CA, Biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion of a $42 million private Series B financing.
>> Click here for more fund... |
| 12.02.2015 |
Cidara Therapeutics Raises $42M
| San Diego-based Cidara Therapeutics, which is developing treatments for fungal and other infections, has raised $42M in a Series B funding. Names of the investors were not announced. Cidara said the funding came from a syndicate of healthca... |
| 11.02.2015 | Antifungals and immunotherapy: Cidara Therapeutics raises $42M Series B | Cidara won’t say who invested in this impressive Series B, just that it’s from “a syndicate of healthcare-dedicated insitutional investors and include both new and existing investors.” The startup’s raising cash fast – just last June, it cl... |
| 11.02.2015 | CIDARA THERAPEUTICS COMPLETES $42 MILLION PRIVATE SERIES B FINANCING | - |
| 11.02.2015 | Cidara Completes $42 Million Private Series B Financing | Proceeds Will Advance Novel Anti-Infectives into Clinical Studies
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion ... |
| 11.02.2015 | Cidara Therapeutics Completes $42M Series B Financing | Cidara Therapeutics, Inc., a San Diego, California-based biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, completed a $42m Series B financing.
Participants in the financing com... |
| 01.07.2014 | Cidara gets $32M to “rewrite the book” on dangerous fungal infections | Indeed, Stein has pivoted from the antibacterials to the antifungal space with the newly christened Cidara. A growing number of patients are in dire need of new antifungal treatments, he said – particularly those with compromised immune sys... |
| 30.06.2014 |
Cidara Therapeutics Gets $32M
| San Diego-based Cidara Therapeutics, a new, startup biopharmaceuticals firm working on treatments for severe fungal infections, has raised $32M in a Series A funding. The funding was led by 5AM Ventures, Aisling Capital, Frazier Healthcare ... |
| 30.06.2014 | Cidara Therapeutics Completes $32M Series A Financing | Cidara Therapeutics, Inc., a San Diego, CA-based biopharmaceutical company, completed a $32m Series A financing.
The round was led by 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners and also included select institut... |
| 30.06.2014 | Cidara Therapeutics Completes $32 Million Series A Financing | Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudbreak™ targeted immunotherapy pl... |
| 30.06.2014 | Cidara Therapeutics Completes $32M Series A Financing Round | Cidara Therapeutics, a privately held bio-pharmaceutical company formerly known as K2 Therapeutics, said it completed a $32 million Series A financing round.
The funding will enable the company to advance drug candidates from the company’s ... |
| - | 5AM Ventures has raised $285M for fifth fund (Updated) | This post has been updated from an earlier version with comments from 5AM Ventures Founder and Managing Partner Andrew Schwab.
Life science venture firm 5AM Ventures has raised $285 million for fund number 5, according to data from a Form D... |
| - | CARB-X dishes out $48M in grants to antimicrobial startups | CARB-X is making it rain.
The international antimicrobial consortium today announced grants totaling $48 million, spread across 11 companies in the U.S. and U.K.
Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteri... |
| - | Aisling Capital launching fourth, $400M life sciences fund | Aisling Capital, a life sciences-focused private equity firm, is raising $400 million for its fourth fund, with a hard cap of $500 million, Fortune reports.
The New York firm has a vast portfolio of healthcare and life sciences startups, wi... |
| - | Cidara gets $32M to “rewrite the book” on dangerous fungal infections | Cidara Therapeutics has emerged from relative obscurity with a new name, a new antifungal drug platform and a $32 million Series A financing round to help bring it to clinical trial over the next 18 months.
The financing will help Cidara ad... |
| - | Antifungals and immunotherapy: Cidara Therapeutics raises $42M Series B | San Diego biotech Cidara Therapeutics just raised an impressive $42 million Series B round – with plans to speed up development of its antifungal and immunotherapy drugs, and bring them to clinical trial later this year.
The startup has two... |
